In this article, we will look at the 12 Most Promising Future Stocks According to Wall Street Analysts.
On August 18, Katie Stockton, Fairlead Strategies founder and managing partner, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends and what the summer rally might mean.
She stated that there has been a persistent uptrend, with the market seeing a breakout in June to new highs. From a technical perspective, there is nothing bearish about new highs.
However, she is skeptical, thinking about sustainability like everybody else. She also added that the breakout did foster additional upside momentum.
READ ALSO: 10 Best Stocks to Invest in For the Long Term and 13 Most Buzzing Stocks to Invest in Right Now.
Stockton further stated that while breadth hasn’t been great, it hasn’t been terrible either, not being wholly related to the mega caps. While there are still giant contributors to the gains this year, breadth has been decent on the whole, and earnings served as a positive catalyst, according to her.
With these trends in view, let’s look at the most promising future stocks according to Wall Street analysts.
A scientist at a computer station, surrounded by a neural network of artificial intelligence code.
Our Methodology
We sifted through stock screeners, financial media reports, and ETFs to compile a list of the most promising future stocks and then chose the top 12 with the highest analyst upside potential. We also added the number of hedge fund holders as of Q1 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is ordered in ascending order of analyst upside.
Note: All data was recorded on August 18.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
12 Most Promising Future Stocks According to Wall Street Analysts
12. Archer Aviation Inc. (NYSE:ACHR)
Analyst Upside: 31.98%
Number of Hedge Fund Holders: 33
Archer Aviation Inc. (NYSE:ACHR) is one of the most promising future stocks according to Wall Street analysts. On August 18, Archer Aviation Inc. (NYSE:ACHR) announced the successful completion of its Midnight aircraft’s longest piloted flight to date. The aircraft flew around 55 miles in 31 minutes at speeds exceeding 126 mph.
Management stated that the flight was conducted at the company’s flight test facility in Salinas, California, in front of Mike Leskinen, Executive Vice President and CFO of United Airlines. Leskinen led the early investment by United Airlines in Archer Aviation Inc. (NYSE:ACHR).
Mike Leskinen stated:
“I’ve been a longtime supporter of bringing sustainable forms of aviation to market. Congratulations to the Archer team on achieving this milestone flight—I was impressed by how quiet the aircraft was.”
The feat marks a significant milestone for Archer Aviation Inc. (NYSE:ACHR), supporting its envelope expansion program as it makes strides toward FAA certification in the US and near-term commercialization in the UAE.
Headquartered in San Jose, CA, and founded in 2018, Archer Aviation Inc. (NYSE:ACHR) develops electric vertical take-off and landing (eVTOL) aircraft.
11. Aurora Innovation, Inc. (NASDAQ:AUR)
Analyst Upside: 86.34%
Number of Hedge Fund Holders: 33
Aurora Innovation, Inc. (NASDAQ:AUR) is one of the most promising future stocks according to Wall Street analysts. On August 3, Evercore ISI analyst Chris McNally maintained a Hold rating on Aurora Innovation, Inc. (NASDAQ:AUR) and set a price target of $8.00.
The rating update came after Aurora Innovation, Inc. (NASDAQ:AUR) announced a notable expansion of its commercial operations on July 30, exceeding driverless miles at the end of June, beginning driverless commercial operations at night, recently expanding its driverless fleet to three trucks, and opening its Phoenix terminal.
Aurora Innovation, Inc. (NASDAQ:AUR) announced that it expanded its driverless operations on the Dallas-to-Houston lane, including nighttime driving in its operations.
The initiative marks more than a doubling in the company’s truck utilization potential, considerably reducing delivery times for long-haul routes and paving the way for profitability for autonomous trucking.
Aurora Innovation, Inc. (NASDAQ:AUR) designs and develops automobile software and hardware, and provides data services. The company also offers the Aurora Driver, an innovative self-driving freight technology that allows a vehicle to drive itself.
10. Corcept Therapeutics Incorporated (NASDAQ:CORT)
Analyst Upside: 89.52%
Number of Hedge Fund Holders: 33
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most promising future stocks according to Wall Street analysts. On August 14, analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT), retaining the price target of $137.00.
The analyst based the rating on Corcept Therapeutics Incorporated’s (NASDAQ:CORT) strategic plans and promising developments, stating that the company made notable progress with its novel glucocorticoid modulator, relacorilant.
The modulator saw improvements in both regulatory and clinical arenas. Nash added that the FDA has also accepted an NDA submission for relacorilant for the treatment of Cushing’s syndrome, and a decision is anticipated by the end of 2025.
The analyst also stated that Corcept Therapeutics Incorporated (NASDAQ:CORT) submitted another NDA for relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer, preparing for a potential launch by mid-2026.
Therefore, the potential of the expansion of relacorilant into oncology further supports the optimistic outlook for Corcept Therapeutics Incorporated (NASDAQ:CORT).
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions.
The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.
9. Legend Biotech Corporation (NASDAQ:LEGN)
Analyst Upside: 105.61%
Number of Hedge Fund Holders: 34
Legend Biotech Corporation (NASDAQ:LEGN) is one of the most promising future stocks according to Wall Street analysts. On August 12, RBC Capital raised the firm’s price target on Legend Biotech Corporation (NASDAQ:LEGN) to $77 from $75, keeping an Outperform rating on the shares.
The analyst told investors in a research note that the Q2 beat by Legend Biotech Corporation (NASDAQ:LEGN) suggests continuing strong demand and successful manufacturing for Carvykti, supporting sustainable growth for the franchise.
The firm added that it continues to anticipate growth in the US, with additional acceleration expected ex-US. It also sees several tailwinds for Legend Biotech Corporation (NASDAQ:LEGN), including pull-through of 5-year OS data.
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.
8. Samsara Inc. (NYSE:IOT)
Analyst Upside: 38.64%
Number of Hedge Fund Holders: 35
Samsara Inc. (NYSE:IOT) is one of the most promising future stocks according to Wall Street analysts. Piper Sandler lowered the firm’s price target on Samsara Inc. (NYSE:IOT) to $47 from $53 on August 7, keeping an Overweight rating on the shares.
The firm told investors that the high-correlation inputs suggest $390 million of revenue or 4.5-5% upside this quarter. It added that the macro-inputs are continually mixed, but some are exhibiting signs of improvement.
Piper Sandler also stated that job postings skew positively, with conversations at Samsara Inc.’s (NYSE:IOT) user conference and with competitors pointing towards durable budgets and interest in suites.
Samsara Inc. (NYSE:IOT) develops internet-connected sensor systems, combining wireless connectivity, plug-and-play sensors, and cloud-hosted software integrated for deployment. The company offers AI-powered safety programs that train and protect employees.
7. UiPath Inc. (NYSE:PATH)
Analyst Upside: 34.29%
Number of Hedge Fund Holders: 41
UiPath Inc. (NYSE:PATH) is one of the most promising future stocks according to Wall Street analysts. In a report released on August 12, Matthew Hedberg from RBC Capital maintained a Hold rating on UiPath Inc. (NYSE:PATH), with a price target of $12.00.
UiPath Inc. (NYSE:PATH) reported a revenue of $357 million for fiscal Q1 2026, reflecting a growth of 6% year-over-year. ARR for the quarter reached $1.693 billion, up 12% year-over-year.
Management also reported $119 million in cash flow from operations, while the non-GAAP adjusted free cash flow reached $117 million.
UiPath Inc. (NYSE:PATH) develops and provides a software platform that automates business processes. Its UiPath Platform™ allows robots, AI agents, people, and models to collaborate and revolutionize industries and enhance human potential as the world moves into an agentic future.
The company also offers claims processing automation, payable automation, finance and accounting automation, and contact center automation.
6. Jazz Pharmaceuticals (NASDAQ:JAZZ)
Analyst Upside: 50.00%
Number of Hedge Fund Holders: 52
Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the most promising future stocks according to Wall Street analysts. On August 14, BofA raised the firm’s price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $225 from $217, keeping a Buy rating on the shares.
The firm told investors in a research note that it spoke with two key opinion leaders after the recent approval of Modeyso to treat an ultra-rare brain tumor. The leaders offered “positive feedback” on Modeyso uptake along with the odds of success for the confirmatory Phase 3 study.
The firm added that while the lead US indication for Modeyso for the recurrent setting is likely to be niche, the call from the experts left it “more assured” about the potential of the confirmatory ACTION trial, which may bolster peak US sales to greater than $400 million.
Jazz Pharmaceuticals (NASDAQ:JAZZ) develops medicines for serious diseases. Its primary marketed products include Xywav, Xyrem oral solution, Epidiolex oral solution, Rylaze, Zepzelca, Defitelio, and Vyxeos liposome for injection.
These medicines treat excess daytime sleepiness (EDS) in narcolepsy patients seven years of age or older, tepatic veno-occlusive disease (VOD), and other ailments.
5. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Analyst Upside: 70.61%
Number of Hedge Fund Holders: 59
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks according to Wall Street analysts. In a report released on August 13, Gena Wang from Barclays maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), with a price target of $86.00.
The rating update came after BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported its fiscal Q2 2025 results on August 4, with total revenues reaching $825 million, up 16% year-over-year and up 17% at constant currency year-over-year.
GAAP diluted earnings per share (EPS) for the quarter was $1.23, up 124% year-over-year, while non-GAAP diluted EPS reached $1.44, up 50% year-over-year.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
4. Hubspot, Inc. (NYSE:HUBS)
Analyst Upside: 50.94%
Number of Hedge Fund Holders: 61
Hubspot, Inc. (NYSE:HUBS) is one of the most promising future stocks according to Wall Street analysts. On August 11, Argus lowered the firm’s price target on Hubspot, Inc. (NYSE:HUBS) to $650 from $865, keeping a Buy rating on the shares.
The rating update came after Hubspot, Inc.’s (NYSE:HUBS) Q2 report, with the firm stating that the company is experiencing traction from its go-to-market and pricing changes.
Argus added that Hubspot, Inc. (NYSE:HUBS) is a sustained double-digit revenue and earnings growth compounder.
HubSpot (NYSE:HUBS) is an American developer and marketer of software products for inbound marketing, customer service, and sales.
Its unified platform offers prime connection for customer-facing teams, and includes artificial intelligence-powered engagement hubs, a connected ecosystem with more than 1,500 app marketplace integrations, a smart customer relationship management product (CRM), a community network, and educational content.
The company’s engagement hubs include Sales Hub, Marketing Hub, Operations Hub, Service Hub, Content Management System Hub, and Commerce Hub. These hubs allow companies to engage and attract clients through the customer lifecycle.
Smart CRM is HubSpot’s primary layer of operations that brings customer data to AI, powering the customer platform with unified customer profiles and tools to manage and govern teams and business processes.
It specializes in relating and selling to mid-market business-to-business (B2B) companies. HubSpot (NYSE:HUBS) functions on a subscription basis.
3. Revolution Medicines, Inc. (NASDAQ:RVMD)
Analyst Upside: 97.53%
Number of Hedge Fund Holders: 61
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the most promising future stocks according to Wall Street analysts. On August 18, Piper Sandler initiated coverage of Revolution Medicines, Inc. (NASDAQ:RVMD) with an Overweight rating and a $75 price target.
Revolution Medicines, Inc. (NASDAQ:RVMD) reported its fiscal Q2 2025 results on August 6, reporting strong execution of two ongoing Phase 3 trials of daraxonrasib.
Management reported that the company is winding down enrollment in the US for RASolute 302 and anticipates the completion of the enrollment of the trial this year.
Revolution Medicines, Inc. (NASDAQ:RVMD) also reported that the FDA Breakthrough Therapy Designations were granted for two RAS(ON) inhibitors, daraxonrasib and elironrasib.
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies. It discovers and develops cancer treatments through novel combination and monotherapy treatment regimens that enhance clinical benefits.
2. Okta, Inc. (NASDAQ:OKTA)
Analyst Upside: 31.32%
Number of Hedge Fund Holders: 65
Okta, Inc. (NASDAQ:OKTA) is one of the most promising future stocks according to Wall Street analysts. On August 18, Barclays lowered the firm’s price target on Okta, Inc. (NASDAQ:OKTA) to $100 from $120, keeping an Equal Weight rating on the shares.
The rating update came ahead of the earnings report on August 26. Barclays added that it sees potential upside for the remaining performance obligations because of healthy federal activity.
Okta, Inc. (NASDAQ:OKTA) provides an identity management platform for enterprises, operating through the International and United States geographical segments.
The company secures the identity of every AI agent across its full lifecycle, irrespective of the task and environment. Its products include multi-factor authentication, single sign-on, API access management, access gateway, authentication, lifecycle management, and more.
1. Atlassian Corporation (NASDAQ:TEAM)
Analyst Upside: 47.78%
Number of Hedge Fund Holders: 82
Atlassian Corporation (NASDAQ:TEAM) is one of the most promising future stocks according to Wall Street analysts. On August 18, Citi analyst Fatima Boolani lowered the firm’s price target on Atlassian Corporation (NASDAQ:TEAM) to $240 from $300, keeping a Buy rating on the shares.
The firm told investors that it updated its models in the software space after the Q2 reports. Atlassian Corporation (NASDAQ:TEAM) reported its fiscal Q4 and full-year 2025 results on August 7, closing out FY25 with more than $5.2 billion of revenue.
It also generated over $1.4 billion in free cash flow and reached 2.3 million AI monthly active users.
Mike Cannon-Brookes, CEO and co-founder of Atlassian Corporation (NASDAQ:TEAM), stated that AI is “fundamentally changing” the world’s workings, which is creating considerable tailwinds for the company in the process.
Atlassian Corporation (NASDAQ:TEAM) provides team collaboration and productivity software, offering products such as Jira Software, Confluence, Jira Service Management, and Loom.
Ranging from space travel and medicine to disaster response and pizza deliveries, the company’s products allow teams from across the globe to advance “humanity” through the “power of software”.
While we acknowledge the potential of TEAM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEAM and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
